Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP
Details : Sohonos (palovarotene) is a selective agonist of RARγ, a receptor expressed in chondrogenic cells and chondrocytes that acts as a transcriptional repressor, which is investigated for the treatment of fibrodysplasia ossificans progressiva.
Product Name : Sohonos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 19, 2023
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sohonos (palovarotene) is a selective agonist of RARγ, a receptor expressed in chondrogenic cells and chondrocytes that acts as a transcriptional repressor. Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia os...
Product Name : Sohonos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2023
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sohonos (palovarotene) is a selective agonist of RARγ, a receptor expressed in chondrogenic cells and chondrocytes that acts as a transcriptional repressor. It decreases BMP signaling and subsequently inhibits the SMAD1/5/8 signaling pathway.
Product Name : Sohonos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 16, 2023
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Palovarotene is authorized for use in appropriate patients in Canada and United Arab Emirates where it is marketed as SohonosTM (palovarotene capsules).4 Investigational palovarotene is under review with a number of regulatory authorities.
Product Name : Sohonos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 23, 2022
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sohonos (palovarotene) is an oral investigational, selective retinoic-acid receptor gamma (RARγ) agonist being developed as a potential treatment for people living with the debilitating ultra-rare genetic disorder fibrodysplasia ossificans progressiva (...
Product Name : Sohonos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2022
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sohonos (palovarotene), an oral selective retinoic-acid receptor gamma (RARγ) agonist approved by Health Canada indicated to reduce the formation of heterotopic ossification in adults and children with fibrodysplasia ossificans progressiva.
Product Name : Sohonos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 24, 2022
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Accepts Ipsen’s Nda for Ultra-Rare Genetic Disorder Drug
Details : Analysis of the primary endpoint data demonstrated a 62% reduction in mean annualised new HO volume in participants treated with palovarotene versus untreated participants from a natural-history study.
Product Name : Sohonos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2021
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The presentation will highlight data from Ipsen’s MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva.
Product Name : Sohonos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2020
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Post hoc analyses showed substantial reduction (62%) in mean annualized new heterotopic ossification volume in patients with FOP who were treated with oral investigational therapy palovarotene.
Product Name : Sohonos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2020
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted at ENDO 2020
Details : The data include a first-of-its kind study highlighting one-year data on the natural progression of FOP and the impact of heterotopic ossification (HO) on patients’ physical functioning over time.
Product Name : Sohonos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2020
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable